Latest News

Alan Bryce, MD, breaks down the key prostate cancer studies that he believes are going to change practice from ASCO 2026.

OMCAZIO demonstrated bioequivalence to CABOMETYX at a lower dose and was found to have no clinically significant food effect.

Recent data suggest that bladder cancer burden is increasing across age groups, with a disproportionate rise among younger women.

Four Urology Times Clinical Forums show that ARPI safety, drug interactions, and cognitive effects, not efficacy alone, guide mCSPC therapy selection.

The approval is supported by data from the phase 3 PSMAddition trial.

Joshua Lang, MD, MS discusses how emerging biomarkers may help personalize treatment decisions while highlighting barriers to precision oncology in prostate cancer.

A reference on the key recommendations from the AUA Testosterone Deficiency guideline.

AI in medicine is here. What happens next matters for the future of health care delivery.

A 10-year registry analysis found focal HIFU and cryotherapy achieved durable cancer control and low prostate cancer mortality in localized disease.

Matthew D. Galsky, MD, discusses how the FDA approval of enfortumab vedotin plus pembrolizumab for MIBC is moving the field beyond cisplatin eligibility and influencing future approaches to surgery and response-guided therapy.

Adanma Ayanambakkam, MD, MS, highlights data from the phase 1 FIT-001 trial evaluating darlifarnib plus cabozantinib in patients with advanced renal cell carcinoma.

This FAQ outlines the major recommendations from PCWG4 for urologists and clinical investigators involved in prostate cancer clinical trials.

Phase 3 BOND-003 data published in The Lancet Oncology showed that intravesical cretostimogene grenadenorepvec produced durable complete responses and a favorable safety profile in patients with high-risk, BCG-unresponsive NMIBC with CIS.